The US Food and Drug Administration has granted approval to Abbott’s next-generation XIENCE Sierra everolimus-eluting coronary stent system.

The new device expands the company’s existing portfolio of XIENCE stents and comes with improved capabilities to treat complex blockages, including cases with several or completely blocked vessels.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

XIENCE Sierra features a thinner profile and improved flexibility with longer lengths and small diameters. The stent obtained the European CE-Mark in October 2017 and Japan’s regulatory approval last month.

“This transcatheter mitral replacement device has been designed to facilitate repositioning and complete retrieval to enable more precise implantation and subsequently improve patient outcomes.”

Abbott vascular business senior vice-president Chuck Brynelsen said: “We developed XIENCE Sierra so that physicians can more easily deliver the stent even in challenging cases.

“The updated design and improved deliverability mean doctors can access and unblock difficult-to-treat lesions with more flexibility and precision than other stents.”

The company has also reported positive data from the initial 100 subjects in a clinical study being conducted to evaluate its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This transcatheter mitral replacement device has been designed to facilitate repositioning and complete retrieval to enable more precise implantation and subsequently improve patient outcomes.

Tendyne does not require open-heart surgery and involves minimally invasive replacement of native mitral valve for reducing symptoms of heart failure.

Results revealed that after 30 days, patients treated with Tendyne achieved significant decrease in mitral regurgitation symptoms and low mortality rates.

The study involves a total of 350 adult symptomatic mitral regurgitation (MR) patients not eligible for open-heart surgery. Its primary endpoints are safety, procedure-related serious adverse events and performance assessment.